
7. Compound according to any one of claims 1-6, wherein R is an organic group comprising one or more peptides, preferably R is SK_m, wherein m is 1, 2, 3, 4 or 5, and wherein R is optionally coupled to an antigen.

8 Compound according to claim 7, wherein group R is represented by



in which R^4 a K_m peptide part, wherein m is 0, 1, 2, 3, 4 or 5, and wherein R^4 is optionally coupled to an antigen and in which R^5 is hydrogen or a group comprising one to six atoms chosen from carbon, nitrogen and oxygen.

9. Compound according to claim 8, wherein R^5 is a $-CH_2$-OH group, a– CH_2-CH_3 group, a–$(CH_2)_3$-CH_3 group, a–$CH_2C{\equiv}CH$ group, a–$CH_2CH{=}CH_2$ group or a –$(CH_2)_2NH_2$ group.

10. Compound according to claim 8 or 9, wherein R^5 is not hydrogen and the asymmetric carbon to which R^5 is attached has the L configuration.

11. Compound according to any one of claims 7-10, wherein the K_m peptide part is coupled to an antigen, a nucleic acid and/or an antibody.

12. Solid phase peptide synthesis process to prepare a compound according to any one of claims 1-11, comprising

(a) providing R-H, which is optionally immobilized and/or side-chain protected;

(b) coupling of substituted cysteine building block Fmoc-(Y-(2-($OC(O)R^2$)-3-($OC(O)R^1$))propyl)-Cys-OH to R-H; and

(c) cleavage of the Fmoc-group from the N-terminus of the resulting peptide; and

(d) treatment of the Fmoc-liberated peptide with H-$(CH_2)_n$-N=C=X, wherein R, R^1, R^2, X, Y and n are as defined in any one of claims 1-10.

13. Process according to claim 12, wherein R is an organic group comprising one or more peptides and R-H is immobilized and/or side-chain protected.

14. Process according to claim 13, further comprising:

(e) conjugating an antibody or a nucleic acid to the H-$(CH_2)_n$-N=C=X-treated peptide.

15. Composition comprising the compound according to any one of claims 1-11 and an antigen either as separate compound or as part of the compound according to any one of claims 1-11.

~~15~~16. Use of the c~~C~~ompound according to any one of claims 1 to 1~~0~~ or a composition ~~comprising a compound~~ according to ~~any one of~~ claim~~s~~ 1~~5~~-~~10~~ for ~~use as~~ the manufacture of a medicament.

~~16. Compound or a composition according to claim 13, wherein an antigen is present as a separate molecule.~~

~~17. Compound according to claim 11 or a composition comprising a compound according to claim 11 for use as a medicament.~~

~~18~~17. Use of~~Compound or~~ a composition according to claim 16~~14 or 15~~, wherein the composition is for use as a preventive or therapeutic vaccine against the antigen.

~~19~~18. Use of a compound according to any one of claims 1-11 and an antigen, either as separate compound or as part of the compound according to any one of claims 1-11, for the manufacture of a vaccine composition ~~A method~~ for the induction, maintenance and/or enhancement of an immune response in a subject against the ~~an~~ antigen and/or for the prevention, delay and/or treatment of a disease or condition associated with the ~~an~~ antigen in a subject

~~wherein a compound or a composition as defined in any one of claims 14 to 16 is administrated to said subject~~.